PTCT logo

PTC Therapeutics Inc. (PTCT)

$60.36

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PTCT

Market cap

$5.04B

EPS

-1.36

P/E ratio

--

Price to sales

5.35

Dividend yield

--

Beta

0.517385

Price on PTCT

Previous close

$60.97

Today's open

$60.63

Day's range

$58.88 - $60.97

52 week range

$58.80 - $90.87

Profile about PTCT

CEO

Matthew B. Klein

Employees

991

Headquarters

Warren, NJ

Exchange

Nasdaq Global Select

Shares outstanding

83544284

Issue type

Common Stock

PTCT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on PTCT

PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date

PTC Therapeutics NASDAQ: PTCT expects to provide 2027 sales guidance for its oral phenylketonuria treatment Sephience in January, as executives seek to convince investors that the drug's strong first year of sales can be sustained.

news source

MarketBeat • Nov 17, 2026

news preview

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company's outstanding shares of common stock, subject to market conditions.

news source

PRNewsWire • Nov 3, 2026

news preview

PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows

PTC Therapeutics (PTCT) is rated Hold, bordering on Sell, with fair value estimated at $52/share versus a $59.97 current price. Sephience's strong launch drives growth, but legacy product declines offset gains; Q4 and 2027 results are key inflection points. PTCT's guidance has been consistently conservative, with actual quarterly sales repeatedly beating top-end forecasts.

news source

Seeking Alpha • Nov 3, 2026

news preview

PTC Therapeutics to Participate in Upcoming Investor Conferences

WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Jefferies Global Healthcare Conference  Monday, Nov. 16 at 11 a.m.

news source

PRNewsWire • Nov 2, 2026

news preview

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its common stock and 11,535 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 13 new employees.

news source

PRNewsWire • Oct 30, 2026

news preview

PTC Therapeutics Q3 Earnings Call Highlights

PTC Therapeutics NASDAQ: PTCT reported third-quarter 2026 total revenue of $358 million, including $276 million in net product revenue, as sales of phenylketonuria treatment Sephience continued to expand in the United States and internationally.

news source

MarketBeat • Oct 30, 2026

news preview

PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript

PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Oct 30, 2026

news preview

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue guidance raised to $960 to $990 million – – Sephience™ (sepiapterin) Q3 2026 revenue of $182 million, with continued growth in the US and ongoing global expansion – – Acquired ST-920 Fabry disease gene therapy; BLA submission expected to be completed in Q4 2026 – WARREN, N.J., Oct. 29, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2026.

news source

PRNewsWire • Oct 29, 2026

news preview

PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates

PTC Therapeutics (PTCT) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.2 per share a year ago.

news source

Zacks Investment Research • Oct 29, 2026

news preview

PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

news source

Zacks Investment Research • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in PTC Therapeutics Inc.

Open an M1 investment account to buy and sell PTC Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PTCT on M1